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The SIOPE Strategic Plan is one of the deliv-
erables of the European Network for Cancer 
research in Children and Adolescents (ENC-
CA), a network of excellence that was 
run from 2011 to 2015 under the EU 7th 
Framework Programme for research and in-
novation (FP7).
This plan was first elaborated by a dedicated 
working group, the ENCCA Long-term Sus-
tainability (LTS) working group. Established 
within the ENCCA project, this group is com-
posed of outstanding experts in paediatric 
oncology: Andrea Biondi, Angelika Eggert, 
Lars Hjorth, Jerzy Kowalczyk, Ruth Laden-
stein, Giorgio Perilongo, Rob Pieters, Kathy 
Pritchard-Jones, Martin Schrappe, Richard 
Sullivan and Gilles Vassal (working group 
chair). 
The first document has been presented, dis-
cussed, and refined through the contributions 
of SIOPE Board members and partners from 
the ENCCA project, the European Clinical Trial 
Groups (ECTGs) and the National Paediatric 
Haematology-Oncology Societies (NaPHOS) – 
both parts of the European Clinical Research 
Council for Paediatric and Adolescent Oncol-
ogy (CRC, formerly ECRC) – the ENCCA Par-
ent Patient Advocacy Committee (PPAC), and 
the Europe Regional Committee of Childhood 
Cancer International (CCI).
On September 18th and 19th, 2014, SIOPE 
organized a conference in Brussels entitled 
‘Joining efforts for a brighter future for chil-
dren and adolescents with cancer – The Euro-
pean roadmap to Horizon 2020’,  in order to en-
sure the sustainability on the long-term of the 
results achieved in the framework of ENCCA. 
On this occasion, approximately 160 partici-
pants from 31 countries – representing all 
stakeholders (patients, survivors, parents, 
academia, charities, industry, regulators, EU 
policy-makers) – endorsed the SIOPE propos-
al and called for a European Cancer Plan for 
Children and Adolescents.
The ENCCA Scientific Advisory Board (com-
posed of Peter Adamson, Ulrik Ringborg, Hol-
ger Schünemann) reviewed the proposal in 
early 2015. 
The pre-final draft was approved by the SI-
OPE General Assembly in October 2014, by 
the ENCCA General Assembly in January 2015, 
and the final version has been approved by 
the SIOPE Board on May 20th, 2015.
The SIOPE Strategic Plan will be launched at 
the 2015 European Cancer Congress in Vienna 
in September 2015 and at the European Par-
liament during a special event of the Mem-
bers of the Parliament Against Cancer (MAC) 
group in November 2015.
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European Network for Cancer research 
in Children and Adolescents
encca
Cancer in young people is rare, but it is still a major health 
issue in Europe. Each year, more than 6,000 young people in 
Europe die of cancer. There are more than 300,000 European 
childhood cancer survivors (in 2020, they will be nearly half 
a million): two-thirds of them have some late side effects of 
treatment, that are severe and impact on the daily life of half 
of those affected.
Within the European Network for Cancer research in Children 
and Adolescents (ENCCA), SIOPE and the European paediatric 
haematology-oncology community have established a long-
term sustainable  Strategic Plan to increase the cure rate and 
the quality of survivorship for children and young people with 
cancer over the next ten years. The ultimate goal is to increase 
the disease- and late-effect- free survival after 10 years from 
the disease, and beyond.
Executive summary
Innovative treatments: to introduce safe and effective innovative treatments (i.e. new 
drugs, new technologies) into standard care;
Precision cancer medicine: to use improved risk classification as well as biological 
characteristics of both the tumour and patient (such as molecular and immunological 
factors) to help guide decisions on which therapies to use;
Tumour biology: to increase knowledge of tumour biology and speed up translation from 
basic research to clinical care to benefit patients;
Equal access: to bring about equal access across Europe to standard care (in both diagnosis 
and treatment), expertise and clinical research;
Teenagers and Young Adults: to address the specific needs of teenagers and young adults 
(TYA), in cooperation with adult oncology;
Quality of survivorship: to address the consequences of cancer treatment such as long-
term side effects, to better understand the genetic background/risk of an individual, and 
to improve quality of life of survivors of childhood cancer;
Causes of cancer: to understand the causes of paediatric cancers and to address 
prevention wherever possible.
Seven medical and scientific objectives have been set up to achieve these goals: 
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SIOPE will steer and coordinate the effective 
implementation of this Strategic Plan, 
together with the European Clinical Trial 
Groups (ECTGs) and the National Paediatric 
Haematology Oncology Societies (NAPHOS) 
in close cooperation with the parents, 
patients, and survivors’ advocates from the 
Europe Regional Committee of Childhood 
Cancer International (CCI). 
Cross-tumour platforms and projects will 
facilitate this implementation: a Clinical Trial 
Facilitating (CTF) platform to ease setting 
up of clinical trials within the new EU Clinical 
Trial Regulation, the PICORET (Population 
Improvement in Childhood cancer Outcomes 
through Research, Evaluation and Training) 
outcome research project to evaluate and 
monitor progress in childhood cancer survival 
and therapy effectiveness, the QUARTET 
(Quality and Excellence in Radiotherapy and 
Imaging for Children and Adolescents with 
Cancer across Europe in Clinical Trials) project 
for quality assurance in radiation therapy, the 
CDDF-SIOPE-ITCC multi-stakeholder platform 
to improve oncology drug development 
for children and adolescents, and the 
‘Ethics, Social Science and Humanities’ 
project to address the ethical aspects 
related to paediatric cancer. An efficient 
IT infrastructure to support e-Health and 
research will be developed, and a European 
Reference Network for paediatric patients 
with cancer will be created to facilitate cross-
border healthcare and access to expertise. 
The ‘Oncopolicy’ programme will ensure that 
the needs of young people are well taken 
into account into all EU policy initiatives in 
the field of health and research. Finally, the 
‘Education and Training’ programme will 
ensure an adequate training to paediatric 
oncology health professionals.
Partnerships will be strengthened with 
patients, parents and survivors’ advocates, 
adult oncologists as well as paediatric 
oncologists from other continents. ‘Intelligent 
and transparent’ public-private partnerships, 
recognizing the specificities of paediatric 
haematology-oncology, will be established 
with industry. The Strategic Plan’s projects 
and structures will be funded through 
European and national grants, as well as by 
charities and industry. 
In conclusion, as a result of several initiatives 
to involve all stakeholders and ensure that 
all their points of view would be taken into 
account in the document, this long-term 
sustainable Strategic Plan has achieved a 
broad consensus, and will serve as a ‘European 
Cancer Plan for Children and Adolescents’.
Gilles Vassal, SIOPE President and ENCCA 
Activity Coordinator
Ruth Ladenstein, SIOPE Board Member and 
ENCCA Coordinator
Martin Schrappe, SIOPE President-Elect and 
ENCCA Activity Coordinator
Kathy Pritchard-Jones, SIOPE Board Member 
and ENCCA Activity Coordinator
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g Each year there are 35,000 new cases of cancer in children and adolescents in Europe   
 (15,000 in children below the age of 15 years and 20,000 in those aged 15-24).
g 1 out of 600 new-borns will develop cancer before turning 20.
g 80% are disease-free after 5 years from diagnosis, thanks to the currently available    
 multidisciplinary treatments:
hToday there are approximately 300,000 EU citizens surviving a childhood cancer.  
     In 2020, they will be nearly half a million; 
hTwo-thirds of survivors have late side effects of treatment, which are severe and     
     impact on the daily life of half of those affected;
hBeyond 5 years from diagnosis, disease-free survivors have higher mortality  
    rates than their non-affected peers.
g 6,000 young people die each year of cancer.
g Despite improving survival rates, cancer is still the first cause of death by disease beyond   
 one year of age in the EU.
g Cancers in children differ from cancers in adults. The most frequent childhood cancers   
 are leukaemias, tumours of the central nervous system (CNS), lymphomas and neuroblas-  
 tomas. They occur from birth to adolescence, with 35% of the typical childhood cancers   
 occurring before the age of five years.
g Considering epidemiology and outcomes, there are three main groups of paediatric cancers:
hThose with a good prognosis (with a higher than 85% chance of survival after five  
     years) under current standard multidisciplinary treatments, using cytotoxic drugs   
 in often an intensive mode (acute lymphoblastic leukaemia, lymphomas,
 retinoblastoma and renal tumours). Over the last five years, the survival rates have
 plateaued for patients suffering from these malignancies, while treatment intensity   
 has been reduced for some patients in order to decrease the risk of long-term
 sequelae; 
Cancer in young people in Europe
Paediatric cancer is still a major public health issue, despite high survival rates 
compared to adult cancers
Figure 1 : Proportion of the 12 main tumour 
groups in children and adolescents in Europe [1]
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hThose with a poor prognosis (~50% or less 5 year survival) such as acute myeloid
 leukaemia, several CNS tumours, neuroblastoma, bone and soft tissue sarcomas.
  Among these diseases, some have a very poor prognosis such as diffuse intrinsic 
 pontine glioma, high-risk neuroblastoma and metastatic sarcomas;
hThe extremely rare tumours, for which there is insufficient information on their real
 incidence and survival.
Figure 2: 5 year age-standardized survival from 
childhood cancers diagnosed in Europe between 
2005 and 2007. Survival for retinoblastoma is calcu-
lated for 0-4 years only, and survival for osteosar-
coma is calculated for 10-14 years only. Figures were 
region weighted and those for  all cancers together 
and CNS cancers were adjusted by case-mix [2]
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h CNS tumours (33%), leukaemias (29%) and neuroblastoma (8%) are responsible for 60%  
     of cancer deaths amongst children aged 0 to 14 years. 
Figure 3: Cause of death by different cancer (Courtesy of Eva Steliarova-Foucher). 
Percentage of all cancer deaths in children (age 0-14) in all 50 areas covered by population-
based cancer registries contributing data for years 2000-2007 to the European Cancer 
Observatory (N=6256) [3]. Causes of deaths are classified according to the ICD-10 (WHO, 1992)
g Five-year survival is generally 10 to 20% lower in Eastern Europe, a disparity that  
     becomes even larger for cancers which already have poor outcomes [2].
g There are already standards of care for paediatric oncology treatment centres [4],  
     but these are not applied equally across Europe [5].
g Teenagers and Young Adults (TYA) aged 15 to 24 years have very specific needs  
    which are not equally addressed across Europe and there are still differences in their 5   
      years survival when compared to younger children with the same malignancy.
Unequal access to standard care and research across Europe
Figure 4: 5-year survival for acute lymphoid leukaemia diagnosed in 2000-2007 in European children by country 
Includes data for 15 860 cases. Data adjusted by age, sex, and period of diagnosis. *Country-weighted [2].
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g Progress has been made over the last 50 years by using intensive chemotherapy regimens   
 (combined with surgery and/or radiotherapy in solid tumours). This includes improved   
 outcomes in some cancers with poor prognosis such as high-risk neuroblastoma (40%   
 survival with highly intensive chemotherapy regimens including immunotherapy) and   
 acute myeloid leukaemia (60% survival with intensive chemotherapy and allogeneic  
 hematopoietic stem cell transplantation).
g Patient survival has plateaued over the last five years or more for difficult-to-treat diseases, 
 which calls for innovative treatments with new mechanisms of action to control resilient   
 and resistant diseases.
There has been little progress regarding difficult-to-treat diseases during the 
last five years
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“Children and adolescents with cancer  
need to be treated within clinical trials and benefit 
from all the facilities required by standard of care.” 
(Marianne Naafs-Wilstra, parent advocate, VOKK, 
The Netherlands)
g Care and research are well integrated on a daily basis, and many high-level basic and   
 translational research teams are dedicated to paediatric malignancies.
g Approximately 350 European public specialised centres in paediatric university hospitals   
 and comprehensive cancer centres take care of patients with a paediatric  cancer, and   
 private practice is extremely rare.
g There is a strong awareness of the needs and challenges for childhood cancer survivors,   
 with dedicated groups (e.g. PanCare, the Pan-European network for Care of survivors   
 after childhood and adolescent cancer) encompassing both healthcare professionals   
 and survivors. 
g Most clinical trials are run at the European level for each malignancy by well-organized   
 European Clinical Trial Groups (ECTGs).
g Up to 90% of newly diagnosed patients are treated according to standard protocols   
 or in prospective clinical trials. Up to 40% of patients are treated within therapeutic trials,   
 both at diagnosis or at relapse, and clinical research is mainly led by academia, with   
 industry-sponsored trials representing less than 5% of biomedical research.
g The paediatric haematology-oncology community is accustomed to working together   
 since more than 50 years, with a strong track record of publishing peer reviewed research.
Though the area of paediatric haematology-
oncology is small, it is extremely complex  
and covers at least 60 different types of  
cancer in a population ranging from new-
borns to teenagers, and even more when 
biological markers (“biomarkers”) are  
considered [6].
Strengths 
Paediatric haematology-oncology 
in Europe
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g There is a lack of sustained and sufficient funding, with high levels of competition for   
 funding and need for prioritisation.
g Healthcare professionals struggle to run investigator-driven clinical trials since the entry into  
 force of the driven EU Clinical Trial Directive (2001/20/EC) in 2004.  
 Although the new EU Clinical Trial Regulation (536/2014/EU) may facilitate academic   
 research when it will be implemented (in 2016), however, it will not address all the existing  
 challenges. 
g There is still poor access to new paediatric drugs in Europe, despite the EU    
 Paediatric Medicine Regulation (1901/2006/EC and 1902/2006/EC) – which nevertheless   
 changed the landscape of childhood cancer drug development in Europe.
g There is insufficient integration between basic biology and clinical research, although   
 there have been several successful EU projects (including KidsCancerKinome, EET-pipeline,  
 ChildHope) funded within the 5th and 6th Framework Programmes.
g There are considerable disparities in Europe in the implementation of research (clinical,   
 translational and basic) and in access to standard care, in particular for TYA.
g Paediatric haematology-oncology is not recognised as a sub-specialty in most countries.
g Parents, patients and survivors’ organisations lack tools and  
 platforms to better join forces with all stakeholders.
g A certain level of fragmentation of research remains, in   
 spite of a long history of networking and major efforts   
 to build together a common infrastructure.
g Paediatric haematology-oncology has grown and achieved   
 successes so far in relative isolation in comparison with the  
 adult oncology community. 
Weaknesses
g The availability of high-throughput technologies that can quickly deal with large numbers of  
 samples will allow new breakthroughs in understanding paediatric tumour biology.
g The development of effective innovative therapies (such as targeted agents and    
 immunotherapy) in adult cancers should be applicable to the treatment of paediatric   
 tumours.
g Paediatric haematology-oncology is now part of the EU agenda, as illustrated by ENCCA – a  
 FP7 network of excellence structuring paediatric cancer research in Europe – and  
 ExPO-r-Net, a DG SANTE project piloting the concept of European Reference Networks ERN)  
 within the scope of the EU Cross-Border Healthcare Directive (2011/24/EU).
Opportunities
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(SHOP), Portugal
g There has been a strong commitment by the Members of the European Parliament to   
 support the paediatric haematology-oncology agenda, for instance via their endorsement   
 of the SIOPE-ENCCA-ICCCPO Manifesto for Paediatric Oncology. 
g Advocacy groups of parents, patients and survivors advocates are increasingly well   
 organized in Europe (through Childhood Cancer International (CCI), formerly ICCCPO)   
 and are strongly committed and equal partners in the European care and research agenda.
g Charities in several countries are committed to support and finance research programmes   
 on cancer in children and teenagers.
g There is a possibility that due to factors such as a high cure rates, decision-making leaders   
 at the European and national levels might consider that paediatric cancer is not a priority,   
 supposing that all efforts should be concentrated only on cancer prevention in adults   
 and on transforming cancer into a controlled chronic disease in the ageing population.
g The global economic crisis hindered the capacity of several EU Member States to improve   
 their healthcare system to deliver standard treatments for young people with cancer.
g There is limited access to some essential medicines, due to drug shortages and to the high  
 price of new medicines.
g Issues around the lack of collection of data in patients with diseases that have a good   
 prognosis under standard treatment mean that the quality of care and, eventually, the   
 probability of cure will be decreased.
g Wide-ranging EU regulatory initiatives might negatively impact the implementation of the   
 goals of the paediatric haematology-oncology community, for example the EU General   
 Data Protection Regulation (2012/0011(COD)) under discussion at the time of publication   
 could impact on research and trials.
Threats
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“The needs of children with cancer have not been 
high on the political radar” (Richard Sullivan, UK)
g To increase the cure rate for young people who have a cancer with a poor prognosis.
g To increase the quality of life for survivors of childhood cancer.
The measure of success will be 10 years free of disease and late side effects.
The seven objectives (with equal importance and weight)
1. Innovative treatments: to introduce safe and effective innovative treatments (i.e. new   
 drugs, new technologies) into standard care.
2. Precision cancer medicine: to use improved risk classification as well as biological   
 characteristics of both the tumour and patient (such as molecular and immunological   
 factors) to help guide decisions on which therapies to use.
3.  Tumour biology: to increase knowledge of tumour biology and speed up translation   
 from basic research to clinical care to benefit patients.
4. Equal access: to bring about equal access across Europe to standard care (in both   
 diagnosis and treatment), expertise and clinical research.
5. Teenagers and Young Adults: to address the specific needs of teenagers and    
 young adults (TYA), in cooperation with adult oncology.
6. Quality of survivorship: to address the consequences of cancer treatment such as long-  
 term side effects, to better understand the genetic background/risk of an individual, and   
 to improve quality of life of childhood cancer survivors.
7. Causes of cancer: to understand the causes of paediatric cancers and to address    
 prevention wherever possible.
The overall goals over the next 10 years 
Overall goals and objectives 
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Key success factors to achieve these objectives
g Both at the European and national levels, there is a need for better integration,    
 coordination and improved long-term sustainability of research. This is especially true   
 when EU funding is more fragmented.
g Commitment from all funding bodies to fund projects and structures relevant to these   
 objectives (including the European Commission, national funding bodies, charities,   
 industry, and investors).
g The profile of paediatric haematology-oncology in the European cancer agenda should be   
 strengthened, and its visibility increased through a more efficient communication strategy.
g A strong partnership with parents, patients and survivors, including better communication  
 and dissemination of information.
g Levels of collaboration with adult oncology should be improved.
g Being part of the global paediatric oncology agenda and developing further collaborations  
 with other continents.
g Building intelligent and transparent partnerships with industry.
g Effective and appropriate European regulations are vital and must be encouraged and   
 engaged with. 
Objective 1: Innovative treatments
To introduce safe and effective innovative 
treatments (i.e. new drugs, new technologies)  
into standard care.
Innovative oncology drugs with new mechanisms of 
action (MOA) are already available for adult cancers, 
and can be more effective than traditional drugs in 
several refractory malignancies. 
The field of drug development is currently expanding beyond well-studied areas like signalling 
pathways, to target patient’s immune system, as well as their unique genetic profile and 
metabolism. Despite recent EU regulatory initiatives that changed the landscape of paediatric 
drug development in Europe for the better, access of children and adolescents with cancer to 
innovative therapies remains insufficient and slow [7].
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Strategy
g To develop and deliver a new drug development strategy – by disease and across  
 diseases – based on the specific biology of patients’ tumour, taking into account existing   
 therapeutic strategies implemented by the ECTGs;  
g To provide a guide for efficient and innovative public-private partnerships between   
 academia and the pharmaceutical industry, within the frame of the EU Paediatric Medicine  
 Regulation.
Actions
1. Across Europe, increase the access of patients to new and innovative therapies, including  
 better referral of patients, and install a molecular and immunological tumour portrait  as 
 a standard of care at the time of relapse as well as at diagnosis for patients with a high-  
 risk  and resistant diseases (link with objective 2);
2. Improve the evaluation of adult cancer drugs for use in the paediatric population,   
 establishing a clear drugs’ prioritisation and avoiding unjustified waivers (not allowing an   
 adult drug to be translated to children);
3. Identify targets in paediatric cancers and, thus, develop specific paediatric anti-cancer   
 drugs (link with objective 3);
4. Develop innovative technologies such a high precision radiation therapy and    
 interventional radiology;
5. Develop innovative designs and methods for efficient studies, both in early phase and   
 phase III clinical trials;
6. Influence changes  in the relevant regulations;
7. Develop international academic collaboration and efficient cooperation with main   
 stakeholders (patients, survivors, parents, academia, charities, industry, regulators, EU   
 decision- and policy-makers).
The European new drug development programme will be implemented by the European 
consortium for Innovative Therapies for Children with Cancer (ITCC), in collaboration with the 
disease-specific European Clinical Trials Groups (ECTGs).
Brought about by ENCCA, the CDDF (Cancer Drug Development Forum)- SIOPE -ITCC  
paediatric oncology platform was created in 2013 with academia, industry, parents and 
regulators in order to make proposals for improving new oncology drugs development for 
children and adolescents [8].
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Risk stratification is used in paediatric haematology-oncology to adapt the intensity of patients’ 
treatment to their own individual risk of failure. It is part of standard of care, is based on the extent 
of the disease and, increasingly, on tumour biology and response (e.g. in neuroblastoma and 
leukaemias) [9] [10] [11]. There has been recent progress in the classification of severalpaediatric 
malignancies (such as medulloblastoma, high grade glioma, ependymoma and rhabdomyosarcoma) 
based on specific aspects of their biology [12]. This will lead to new “biomarkers” that can be used 
in clinical practice to improve risk stratification and to better adapt existing and new treatments 
(objective 1) to each patient. 
Objective 2: 
Precision cancer medicine
To use improved risk classification as well 
as biological characteristics of both the 
tumour and patient (such as molecular 
and immunological factors) to help guide 
decisions on which therapies to use.
Strategy
g To analyse the specific biology (molecular profiling) of both the patient and tumour at   
 the point of diagnosis and throughout treatment to improve risk stratification for adapted  
 individual treatment by identifying:
hPatients with a high probability of cure with standard treatment, who may be  
     proposed new or reduced interventions to decrease the risk of late effects;
hPatients with a poor prognosis tumour to whom innovative therapies should be  
     proposed as early as possible, to increase their probability of cure.
Actions
1. Run prospective clinical trials with innovative design and methods to confirm the use of     
  biomarkers and algorithms in risk stratification, treatment allocation and disease    
 monitoring;
2. Enhance the collaboration between specialists such as biostatisticians, clinicians and   
 biologists;
3. Expand the availability and accessibility of biomarkers for clinical and research use by   
 setting up a network of the necessary molecular laboratories;
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Objective 3: Tumour biology
To increase knowledge of tumour biology and 
speed up translation from basic research to clinical 
care to benefit patients. 
Cancers in adults result from processes that have multiple 
steps, mainly following exposure to external carcinogens 
(tobacco, alcohol, UV, diet, etc.) and often progression 
over many years. 
In contrast, paediatric cancers develop early in life and over a much shorter time period, 
suggesting that fewer and stronger events are required for progression. They are rare, and most 
show fewer genetic defects and a lower genetic complexity as compared to adult cancers[13]. 
Major progress has been made in understanding paediatric tumour biology, leading to the 
discovery of unique cancer hallmarks that are also involved in cancer formation in adults, 
such as the RB1 gene in retinoblastoma and, more recently, Histones H3 mutations in diffuse 
intrinsic pontine gliomas [12]. These advances have already resulted in new classification of 
several diseases. Additionally, the role of the immune system in controlling tumour growth is 
now well-established in many adult cancers, and the challenge is to translate this new findings 
into successful therapies.
Strategy
g To use modern and innovative technologies to further uncover the mechanisms of   
 paediatric tumour development, progression and relapse. Also, to explore the genetic   
 and cellular heterogeneity within the same tumour, the regulation of genes (epigenetics),  
 and the role of the immune system, metabolism and the tumour’s own surroundings   
 (micro-environment); 
4. Develop research in functional imaging, set up a European imaging platform as well as a   
 platform for quality control in radiation therapy;
5. Improve data sharing, especially those that are linked, such as genomic and clinical data,   
 and widen access of such information to researchers; 
6. Facilitate international academia-led clinical trials (via facilitated submission processes,   
 shortening the time needed from conception to launch);
7. Widen access to tumour samples and nucleic acids for researchers.
This strategy will be implemented by the ECTGs developing research in each paediatric 
malignancy, and it will be facilitated by the cross-tumour European platforms and programmes 
set up within SIOPE.
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Credit Czech Working Group for Paediatric Oncology, 
Czech Republic
Objective 4: Equal access
To bring about equal access across Europe to standard 
care (in both diagnosis and treatment), expertise and 
clinical research.
Treating children with cancer is a complex matter, and needs  
the expertise of a highly specialised multidisciplinary team.  
Across Europe, there is a 10 to 20% difference in 5 year survival, 
between countries with population-based cancer registration – 
the differences may be much greater where no such outcome
data  currently exist. SIOPE led the  preparation, definition and dissemination of the ‘European 
Standards of Care for Children with Cancer’, and a recent SIOPE survey within the European 
Partnership for Action Against Cancer (EPAAC) showed that there is a wide disparity in the 
implementation of these standards of care across different European countries [4].
g To accelerate the translation of results from research to clinical care and allow patients to  
      benefit from new knowledge in a timely fashion.
Actions
1. Strengthen international networks of basic research teams, grouping them by different   
 cancer types, and improve access to new pharmaceutical compounds for preclinical   
 research;
2. Enhance interactions between bio-informaticians, system biologists and developmental   
 biologists;
3. Increase interactions between basic scientists and clinical researchers;
4. Share the clinical-biological data generated by the introduction of technologies that   
 analyse the biology of specific tumours (such as high-throughput sequencing and other   
 tumour profiling technologies) between clinicians and researchers;
5. Improve the access of researchers to relevant and high quality clinically annotated    
 biological samples (including tumour samples, circulating cells, circulating DNA); 
6. Increase the involvement of patients and ents in the precision cancer medicine agenda.
Within ENCCA, several networks of tumour researchers that connect basic and translational 
research teams with a common interest in each paediatric malignancy have been developed.
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Strategy
g To ensure that all centres in Europe that treat children and TYA with cancer meet the  
      European Standards of Care for Children with Cancer;
g To develop pathways that, for complex treatments and rare diseases/situations, allow
access to specialised expertise, specialised technologies (i.e. specialised surgery, 
radiotherapy techniques, haematopoietic stem cell transplantation) or clinical research 
(i.e. early phase trials of new treatments).
Actions
1. Build a European Reference Network (ERN) in paediatric haematology-oncology within the  
 EU Cross-Border Healthcare Directive (2011/24/EU):
hCreate tumour boards by disease – to be considered at three levels: institutional,  
 national and European – in order to provide advice on the best appropriate    
 treatment and care for individual patients;
h Identify centres that are able to deliver standard care and treatments (specialist   
 centres) as well as hubs of coordination, which will also deliver complex treatments   
 and specialised technology;
h Improve referral to specialist centres and hubs of coordination within EU member   
 states and across borders;
hSet up an efficient e-Health and IT platform;
2. Warrant availability of essential medicines for all patients;
3. Specifically address the needs of children and adolescents with extremely rare cancers  
 (e.g. adult cancers such as thyroid cancer, breast cancer and melanoma – occurring   
 extremely rarely in the paediatric population – and extremely rare specific paediatric   
 malignancies such as pleuropulmonary blastoma, etc.);
4. Ensure that paediatric cancer registries cover all European countries, in order to    
 adequately monitor the effects of the present Strategic Plan, and ensure that each   
 National Cancer Plan addresses the specific needs of children and adolescents with cancer;
5. Significantly improve access to palliative care for young patients at the end of their lives;
6. Provide high quality training for all health professionals across Europe, and make    
 paediatric haematology-oncology a recognised sub-specialty.
The ExPO-r-Net project, funded by DG SANTE, is currently piloting the concept of a European 
Reference Network (ERN) in paediatric haematology-oncology, which specifically addresses 
the topic of extremely rare cancers and long-term follow-up.
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“All European children and young people with cancer should have access 
to standards of care, expertise and clinical research.” (Participants at the 
SIOPE-ENCCA Conference, 18-19 September 2014)
Objective 5: Teenagers and Young Adults
To address the specific needs of teenagers and young adults  
(TYA), in cooperation with adult oncology.
Although cancer in teenagers and young adults is rare, it is a substantial 
cause of death in this population. Outcomes are often poorer than 
in younger patients with the same cancer, and several contributory 
factors have been identified: the type of tumours, their biology and 
sensitivity to current therapies, as well as the low participation of TYA 
in clinical trials [14] [15]. TYA have specific and unmet needs, including 
complex psychological and social supportive care. Their position 
between adult and children’s services in healthcare systems does not 
allow for the best possible provision of care or dedicated research 
that could improve their quality of survival. 
Strategy
g To develop a comprehensive multidisciplinary European programme, tackling all issues   
 and specific needs of the TYA population. This will be a joint integrated programme   
 between paediatric and adult oncology, in strong partnership with patients.
Actions
1. Create a European multidisciplinary network on TYA cancers that covers care and research  
 and includes all health professionals and patients;
2. At the national level, help the creation of TYA cancer services, which provide the required   
 complex multidisciplinary care;
3. Define a training programme for health professionals addressing the specific needs of TYA;
4. Increase the portfolio of clinical trials for TYA, and increase their accessibility to all TYA   
 patients;
5. Monitor progress in TYA terms of survival, using the clinical epidemiology platform   
 (defined later in this document).
Within ENCCA a pilot project has been initiated in order to build the European Network for 
Teenagers and Young Adults Cancer [14]. 
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Objective 6: Quality of survivorship
To address the consequences of cancer 
treatment such as long-term side effects,  
to better understand the genetic background/
risk of an individual, and to improve quality 
of life of survivors of childhood cancer.
With an 80% survival at five years, the number of childhood cancer survivors (currently 
estimated to be more than 300,000 in Europe) is likely to continue to increase, and  
improving their quality of life is a major goal. Two-thirds of survivors have late-occurring side 
effects due to their treatments, which are severe in half of them, and have a strong impact on 
their daily lives. It is anticipated that in 2030 there will be around 750,000 paediatric cancer 
survivors in Europe. 
The PanCare network was created in 2008 to address this issue [16]. PanCare is a pan-European 
multidisciplinary network of health professionals, survivors of paediatric cancer and their 
families, who collaborate to reduce the frequency, severity and impact of late treatment side 
effects, with the aim of ensuring that every survivor of childhood cancer receives the best 
possible long-term care. In addition, several survivors’ associations were created recently to 
empower survivors and to help them tackle the issues raised above.
Strategy
g To improve awareness of the needs of childhood cancer survivors, together with them,   
 and facilitate research on it;
g To empower survivors to take the responsibility for their own follow-up, ensuring that they 
 are well-informed on what to be aware of, how and when to access care and follow-up,   
 and who to turn to if and when they need to;
g To encourage health organisations to address the issues of long-term follow-up and ease   
 the transition to adult medicine;
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Objective 7:  Causes of cancer
To understand the causes of paediatric
cancers and to address prevention 
wherever possible.
“Why does my child have cancer?” is a crucial question for parents, which most of the time 
receives no answer. Relatively few causative factors have been identified so far for childhood 
cancers. 
g To run prospective clinical research to reduce the likelihood of long-term side effects in   
 patients who have a good prognosis malignancy.
Actions
1. Establish guidelines for follow-up that cover all possible late-occurring side effects of   
 current treatments;
2. Create and provide a ‘Survivorship Passport’ for each child and adolescent treated for   
 cancer that will include:
hHistory and summary of the patient’s disease as well as treatments received;
hRelevant follow-up measures, including precautionary measures to improve their  
     quality of life;
hA database to store the patient’s clinical data and help monitoring and research;
3. Set up a relevant model of care to allow for a smooth transition to adult medicine (such as  
 ‘long-term follow-up clinics’);
4. Increase research on late-occurring side effects (for example cardiac toxicity, secondary   
 tumours and infertility) and on quality of survival, including societal and psychological   
 aspects;
 5. Anticipate long-term toxicities of innovative therapies, such as targeted therapies, that will  
 be introduced in standard treatments;
Two ongoing FP7 European projects, PanCareSurFup and PanCareLIFE, carry out research 
on late-occurring side effects [17]. The pilot initiative of the ‘Survivorship Passport’ is being 
developed thanks to the support of ENCCA and PanCareSurFup, and the organisation of care 
including a virtual late-effects advisory centre, will be also addressed within the ExPO-r-NET 
project.
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“Survivors of childhood cancer want a normal life.”  
(Sabine Karner, PPAC/CCI/PanCare, Austria)
It is estimated that 4-8% of paediatric cancers occur within a known genetic predisposition 
and more than 100 genetic syndromes with a risk of cancer in childhood are known. The 
proportion may increase as more and more rare cancer gene mutations are discovered 
through ongoing analyses in areas such as genomics. Some studies already suggest that 
up to one in four children and adolescents with a history of cancer may have a genetic 
predisposition condition [18]. The identification of the genetic basis of rare inherited cancers 
in children has revealed key pathways that are shared with sporadic tumours, even in adults. 
Sequencing of the whole genome will generate new information that can be used to improve 
care and to identify new genetic hallmarks of cancer, which can be turned into targets for 
new therapies.
Strategy
g To increase research focused on predisposition to childhood cancer and on the oncogenic   
 drivers that increase the risk of childhood cancer by:
hUsing whole genome sequencing to further uncover genetic predisposition to   
 paediatric cancers;
hCarefully addressing the pragmatic and ethical issues of genetic testing and    
 counselling, anticipating that DNA testing is becoming widely available;
hAddressing questions on the environmental causes of paediatric cancer through   
 scientifically-led and evidence-based studies.
Actions
1. Create a European consortium on genetic predisposition to childhood cancers in order to   
 coordinate research and guide implementation of new knowledge in the clinical setting;
2. Provide guidelines and train health professionals on how to identify patients with a   
 possible genetic predisposition, and how to inform parents;
3. Improve access to paediatric oncogeneticists and genetic testing in Europe;
4. Develop new strategies for prevention and monitoring, including through early diagnosis   
 and screening;
5. Run high-resolution studies through the SIOPE clinical epidemiology platform (defined   
 later in this document), to determine the role of external risk factors.
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 “Childhood cancer survivors in Europe should have access 
to adequate follow-up.”  (PanCare partners: Sabine Karner, 
Austria; Lars Hjorth, Sweden; Riccardo Haupt, Italy)
g Coordinating the implementation of the European Strategic Plan;
g Steering the integration of research, care and education, and increase  
      funding levels;
g Ensuring that the EU legislative framework facilitates the  
      implementation of the Strategic Plan;
g Strengthening partnerships with all stakeholders.
SIOPE is the European Society of Paediatric Oncology and is dedicated to 
care, research and training in paediatric haematology-oncology as well as 
policy-making for decisions that impact on cancer (‘oncopolicy’).
Its mission is to ensure the best possible care and outcome for all 
children and young people with cancer in Europe, by increasing the cure 
rate and the quality of cure of children with cancer. More specifically, 
SIOPE is in charge of:
Coordination and implementation  
of the Plan 
SIOPE is the European branch of the International Society of Paediatric Oncology (SIOP) and a 
founding member of the European Cancer Organization (ECCO).
Currently there are 19 European Clinical Trial Groups (ECTGs) developing clinical and translational 
research either by an individual disease type (15 groups) or across multiple diseases (4 groups), 
who define and run their own research strategy according to the SIOPE Strategic Plan. In Europe 
there are also 25 National Paediatric Haematology-Oncology Societies (NaPHOS). The Chairs of 
ECTGs and NaPHOS form the SIOPE Clinical Research Council (CRC, formerly ECRC). 
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“Children are desperate to enrol in new clinical trials, that 
in some cases can be the only hope for survival.” (Glenis 
WiIlmott, Member of the European Parliament, UK)
The European Clinical Trial Groups
Tumour Name Group Name Website
Brain Tumour SIOPE Brain Tumour Group www.siope.eu/european-
   research-and-standards/european-
   clinical-research-council/ecrc/
   siope-brain-tumour-group 
Ewing Tumour EURO- E.W.I.N.G. www.euroewing.eu/clinical-trials/ 
   ee2012-trial
Germ Cell Tumours Germ Cell Tumours 
Hodgkin ’s Lymphoma  EHL – European Hodgkins www.kinderkrebsinfo.de/index_eng.html   
  Consortium, EuroNet-PHL 
Langerhans Cell Histiocytosis Histiocyte Society www.histiocytesociety.org 
Leukemias and Lymphomas  I-BFM – The International  www.bfm-international.org
  BFM Study GROUP
Liver Tumours  SIOPEL – SIOPE-Epithelial  www.siopel.org
  Liver Tumour Study Group 
Myelodysplasia EWOG-MDS ewog-mds.de 
Neuroblastoma SIOPEN – SIOP Europe www.siopen.org 
  Neuroblastoma Group
Non-Hodgkin Lymphoma EICNHL – European Inter-group 
  Cooperation on Childhood 
  and Adolescent Non Hodgkin 
Osteosarcoma EURAMOS – European and www.euramos.org
  American Osteosarcoma 
  Study Group 
Renal Tumours SIOP-RTSG – SIOP Renal www.siop-rtsg.eu  
  Tumours Study Group  
Retinoblastoma EURbSG – European
  RetinoBlastoma Group 
Soft Tissue Sarcoma CWS – Cooperative Weichteilsarkom 
  Studiengruppe or Cooperative soft Tis
  sue Sarcoma StudyGroup  
Soft Tissue Sarcoma EpSSG – European Paediatric Soft  www.epssgassociation.it 
  Tissue Sarcoma Study Group 
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Across diseases: 
Topic Group Name Website
New Anticancer Agents ITCC – Innovative Therapies for  www.itcc-consortium.org 
  Children with Cancer 
Stem Cell Transplantation EBMT – European Group for Bone  www.ebmt.org
  Marrow and Stem Cell Transplantation 
  Paediatric Working Party 
Survivorship and Late Effects PanCare – Pan-European Network  www.pancare.eu/en
  of for Care of Survivors after 
  Childhood and Adolescent Cancer  
Very Rare Paediatric Tumours EXPeRT – European Cooperative 
  Study Group on Paediatric Rare Tumours) 
The National Paediatric Haematology-Oncology Societies (NaPHOS)
Country NaPHOS/Group Website
Austria AGPHO (Austrian Group for Paediatric  www.docs4you.at
  Haemato-Oncology)  
Belgium BSPHO (Belgian Society of Paediatric  www.bspho.be
  Haematology Oncology) 
Bulgaria Bulgarian Society of Paediatric Oncology 
Croatia Croatian National Group 
Czech Republic CPH (Czech Working Group for Paediatric Oncology) 
France SFCE (Société Française de lutte contre les Cancers  sfce.sfpediatrie.com
  et leucémies de l’Enfant et l’adolescent) 
Germany GPOH (Gesellschaft für Pädiatrische Onkologie  www.kinderkrebsinfo.de/gpoh_society/ 
  und Hämatologie) gpoh_who_we_are/index_eng.html
Greece Hellenic society of Pediatric Haematology-Oncology www.eepao.gr
Hungary HPOG (Hungarian Paediatric Oncology Network) 
Israel ISPHO (Israel Society of Pediatric Hematology  www.ispho.org.il/english
  and Oncology) 
Italy AIEOP (Associazione Italiana Ematologia Oncologia  www.aieop.org
  Pediatrica)  
Latvia Latvian Society of Paediatric Oncology www.ihot.lt/lt/bspoh 
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The National Paediatric Haematology-Oncology Societies (NaPHOS)
Country NaPHOS/Group Website
Austria AGPHO (Austrian Group for Paediatric  www.docs4you.at
  Haemato-Oncology)  
Belgium BSPHO (Belgian Society of Paediatric  www.bspho.be
  Haematology Oncology) 
Bulgaria Bulgarian Society of Paediatric Oncology 
Croatia Croatian National Group 
Czech Republic CPH (Czech Working Group for Paediatric Oncology) 
France SFCE (Société Française de lutte contre les Cancers  sfce.sfpediatrie.com
  et leucémies de l’Enfant et l’adolescent) 
Germany GPOH (Gesellschaft für Pädiatrische Onkologie  www.kinderkrebsinfo.de/gpoh_society/ 
  und Hämatologie) gpoh_who_we_are/index_eng.html
Greece Hellenic society of Pediatric Haematology-Oncology www.eepao.gr
Hungary HPOG (Hungarian Paediatric Oncology Network) 
Israel ISPHO (Israel Society of Pediatric Hematology  www.ispho.org.il/english
  and Oncology) 
Italy AIEOP (Associazione Italiana Ematologia Oncologia  www.aieop.org
  Pediatrica)  
Latvia Latvian Society of Paediatric Oncology www.ihot.lt/lt/bspoh 
Country NaPHOS/Group Website
Luxembourg  Foundation Kriibskrank Kanner www.fondatioun.lu
(SIOPE institutional  
membership)
The Netherlands SKION (Stichting Kinderoncologie Nederland) www.skion.nl 
Nordic countries  NOPHO (Nordic Society of Paediatric www.nopho.org
(Denmark, Norway,  Haematology & Oncology)
Sweden, Iceland, 
Finland)  + Lithuania   
Poland Polish Society of Paediatric Oncology 
  and Haematology 
Portugal SHOP (Sociedade de Hematologia e Oncologia www.spp.pt  
  Pediatrica) 
Romania Romanian Society of Paediatric
  Haematology-Oncology 
Serbia Serbian Society of Haematology and Oncology 
Slovak Republic Slovak Paediatric Association – Section of Paediatric 
  Haemato-Oncology 
Slovenia Slovenian Society of Paediatric Oncology 
Spain SEHOP (Sociedad Española de Hematología  www.sehop.org
  y Oncología Pediátricas) 
Switzerland SPOG (Schweizerischen Pädiatrischen  www.spog.ch
  Onkologie Gruppe) 
Turkey TPOG (Turkish Paediatric Oncology Group) www.tpog.org.tr 
United Kingdom  CCLG (Children’s Cancer and Leukaemia Group)  www.cclg.org.uk
& Ireland   
29A EUROPEAN CANCER PLAN FOR CHILDREN AND ADOLESCENTS
 “Researchers are an essential driving force in making successful cure 
for childhood cancer possible.” (Hermann van Rompuy, former President 
of the EU Council, Belgium)
From an international perspective, paediatric oncology research in  
Europe is in good standing. Between 2005 and 2014, there were 
32,785 academic papers about paediatric oncology, representing 4.6% 
of all oncology papers and 7.1% of all paediatric papers. 22% of those 
articles came from Europe and 32% from the US [19]. 
In 2008, funding for paediatric oncology research was estimated, using previously validated 
econometric analysis of research activity [20], to be 1,229 USD millions, with more than 50% 
from public funding, including international funding such as European framework funding and 
just under 20% from the pharmaceutical industry [21]. In 2013, this has been estimated to have 
dropped to 900 USD millions, a decline over 25% over five years.
Research output is growing, particularly in clinical research, but availability of short-term fund-
ing is getting worse despite more European programmes. In addition, most of the public policy 
discourse has been focused on an ageing European society and the needs of children with can-
cer are not high on the political radar, despite the fact that cancer is the leading cause of death 
by disease in the young population. Globally, childhood cancer is being heavily marginalised.
The SIOPE objectives are:
g To improve public, political and policy visibility of childhood cancer research;
g To show the existing linkage between research activity and better outcomes for children  
       with cancer in Europe;
g To develop strategies in order to broaden research engagement;
g To address both pan-European research funding and national funding streams, as well as  
      funding from charities.
Childhood cancer from  
a societal perspective 
Figure 5: Pie chart of national contributions to paediatric oncology research, 
2005-14; fractional counts.  European countries coloured blue with shading; North 
American countries red with shading; Asian countries yellow with shading.  
Credit: Institute of Cancer Policy, London, UK
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Facilitating platforms and cross-tumour 
research projects
Platform to facilitate the implementation 
of ECTGs research strategy: the Clinical 
Trial Facility (CTF) Platform
This platform will help institutions to set up 
international clinical trials in the framework of 
the new EU Clinical Trials Regulation (536/2014/
EU), and will allow researchers to share their 
experiences and solutions to issues related 
to the Regulation’s implementation. It will 
provide templates and advice for the hurdles 
faced (e.g. practicalities and contracts) when 
implementing non-commercial clinical trials 
across multiple countries and sites, including 
the specific issues arising when trials are 
run in partnership with the pharmaceutical 
industry. Within ENCCA, a consortium of five 
European academic institutions has been 
created to speed up the implementation of 
early phase investigator supported trials.
Clinical epidemiology platform for 
outcome research – The PICORET project 
The Population Improvement in Childhood 
Cancer Outcomes through Research, 
Evaluation and Training project (PICORET) will 
address the needs of clinical epidemiology and 
outcome research in paediatric haematology-
oncology. Several paediatric cancers have 
a high survival rate with treatments that 
have been established through prospective 
European randomised trials. Population-
based cancer registries measure overall but 
not relapse-free survival, and so there isn’t 
sufficient information on the effectiveness of 
first line therapy at a population level. 
PICORET will monitor the survival of all 
children and adolescents with cancer 
in Europe and evaluate progress across 
Europe using information from registries 
and observational studies that use standard 
treatments. Such ‘non-interventional’ 
clinical studies can assess effectiveness of 
biomarkers, which can be used for prognosis, 
and allow analysis of traditionally hard-to-
research areas, such as surgical and imaging 
techniques. 
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Through building enhanced clinical registry 
capabilities, PICORET will prospectively 
collect detailed clinical and biological 
information that can be used for quality 
improvement of diagnostics and treatment 
pathways for patients treated by a standard 
treatment  outside of clinical trials. PICORET 
will monitor the survival of all children and 
adolescents with cancer in Europe, and 
will evaluate and compare the quality and 
effectiveness of treatments. High resolution 
studies will be run. 
Initially, PICORET will focus on renal tumours, 
neuroblastoma and medulloblastoma as its 
first exemplars. It will develop standardised 
clinical guidelines as well as a standardisation 
and quality programme in standard care, with 
a special focus on infant dosing. Twinning 
between institutions in countries with higher 
and lower survival rates will be introduced.
Data privacy will be carefully monitored, and 
the project’s impact will be assessed.
Platform for quality assurance in 
radiotherapy – The QUARTET project
Quality assurance and quality control are 
mandatory when patients receive radiation 
therapy. This is to make sure that each 
patient gets the best treatment in terms of 
maximising effectiveness and minimising 
long-term side effects. However, they are not 
systematically performed within clinical trials 
and various programmes are implemented 
only in a limited number of EU countries. 
The QUARTET project (‘QUAlity and excellence 
in RadioTherapy and imaging for children 
and adolescents with cancer across Europe 
in clinical Trials’) aims to build a radiation 
therapy quality assurance programme across 
all paediatric malignancies. It will be run in 
partnership with the European Organisation 
for Research on Treatment of Cancer (EORTC) 
and Aquilab for patients participating in 
clinical trials using radiation therapy and 
run by ECTGs. Eventually, the platform will 
expand its activity to patients treated outside 
of clinical trials.
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Multi-stakeholder platform for new 
paediatric oncology drug development – 
The CDDF-SIOPE-ITCC platform
This multi-stakeholder platform was created in 
December 2013 by Cancer Drug Development 
Forum (CDDF), SIOPE and ITCC as a deliverable 
of the ENCCA project to improve oncology drug 
development for children and adolescents 
[8].  Academia, parents and survivors, industry 
and regulators are equally represented and 
work together on the following objectives:
g To set up drug prioritisation and   
 enable drug development, based on the  
 mechanism of  action of the drug as well  
 as biological factors;
g To propose changes in the EU Paediatric  
 Medicine Regulation to better address  
 the needs   of those with life threatening  
 diseases;
g To propose new incentives for the   
 development of specific paediatric drugs  
 and repurposing of existing drugs;
g To implement long-term follow up   
 measures for new oncology drugs for  
 children and  adolescents.
Ethics, Social Sciences and Humanities 
programme
This is a natural development of the ethics 
programme set-up within ENCCA to maintain 
and improve the level of expertise on ethics 
in the field of paediatric cancer care and 
research. It is based on two priorities, namely 
to reflect the multidisciplinary nature of social 
sciences and humanities where suitable to 
paediatric oncology, and to facilitate access to 
appropriate expert views from professionals 
and from patients’ representatives on ethical 
issues. 
 
Following these priorities, “ethics” is meant 
as a multidisciplinary approach to the 
non-technical issues related to the care, 
protection, and self-realisation of paediatric 
oncology-haematology patients (or former 
patients). It is proposed to develop a non-
prescriptive, participatory and outcomes-
oriented approach to these issues, harnessing 
the relevant knowledge and expertise in the 
Social Sciences and Humanities (SSH) field. 
Four main topics will be addressed by this 
programme: i) return of research results, 
ii) personal data in care and research 
environments, iii) access to medical inno-
vation, iv) care and healthcare pathways. 
The programme will be performed through 
objective assessment of the non-technical 
issues related to the care and quality of 
survival of children and adolescents with 
cancer, as well as through community-based 
participatory research actions within the 
paediatric oncology community.
In accordance with the successful imple-
mentation within ENCCA, the programme 
will be steered and run by a permanent 
contact point along with ad-hoc academic 
collaborations. A steering Legal and Ethical 
Advisory Board will peer-review the projects 
and the results. The following tools will be set 
up: i) a thematic database of ethics expertise 
in Europe, identifying expert individuals and 
centres in Western and Eastern European 
Universities, ii) a database of local initiatives 
for bedside and benchside ethics, accessible to 
professionals and patients, iii) an initiative to 
establish multi-centre collaborations on non-
technical interventions (fostering experience-
sharingand multicentre evaluation). 
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All this is expected to generate sustained 
community dialogue, concerted evidence 
generation as well as transverse capacity-
building on non-technical domains, first of all 
on ethical issues. 
The SIOPE portal
The portal set-up within the ENCCA project 
will be transferred to SIOPE after the end 
of the ENCCA project (December 2015). 
This online ‘one-stop-shop’ portal will support 
communication and interaction between 
everyone involved in implementing the 
strategic research agenda. It will serve as a 
resource for documentation and as a platform 
for information exchange.
Each patient will have a unique ID (EUPID) so 
that their data can be anonymised and shared 
between different databases. A pilot project 
for an integrated IT structure that will allow 
information to be linked between sources 
(such as registries, clinical trial databases, 
hospital electronic health records) and users 
(such as researchers and analysts) is being 
developed by the IT providers of ENCCA.
Within ENCCA, a consultation IT platform has 
been developed for patients with haepato-
blastoma (a very rare disease) by SIOPEL 
along with CINECA. This platform (including 
pathology slides and images) facilitates access 
to expert advice for diagnosis and treatment, 
including indications of liver transplant. This 
IT tool is further developed within the ExPO-r-
Net project for retinoblastoma and extremely 
rare paediatric tumours, and will eventually be 
adapted for other diseases within the Paediatric 
Oncology Europe Reference Network. 
In addition, an IT platform for virtual tumour 
boards will be developed.
Based on these experiences and following 
those pilot projects, SIOPE and ECTGs will define 
how to structure the best IT environment that 
will allow the implementation of the Strategic 
Plan.
Network of biobanks
Samples from patients and tumours, which are 
labelled with additional clinical information, 
are vital for the success of the SIOPE Strategic 
Plan. The aim of SIOPE is therefore to support 
a network of biobanks that can share data 
electronically, in keeping with EU data 
protection laws. The difficulty of the task is 
not underestimated. 
A vital step in the development of such a 
network within SIOPE is the introduction 
of a unique patient identifier (the above 
mentioned EUPID) for every paediatric cancer 
patient treated in Europe, as well as the 
development of standardised patient consent 
forms. These must be in line with national 
data protection laws in European countries, 
and allow for new developments in molecular 
analysis of tumour samples (particularly next-
generation sequencing),  as well as the wishes 
of patients and parents and other ethical 
considerations. 
In addition to this, ENCCA guidelines are 
currently being finalised on the standards for 
tumour and other patient samples (e.g. blood 
and plasma) as well as related materials like 
DNA and RNA, and on the process of access 
and use.
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Oncopolicy programme
Several regulatory initiatives are of direct 
concern to paediatric haematology-
oncology and the implementation of the 
SIOPE Strategic Plan. SIOPE has developed 
expertise and skills to monitor and influence 
the development of relevant European 
cancer health and research policy themes, 
and to ensure that the needs of the paediatric 
haematology-oncology community are taken 
into account when regulations are drafted or 
revised: 
g Each National Cancer Plan should address  
 the needs of children and adolescents  
 with cancer, according to the European  
 Cancer Plan.
g The Cross Border Healthcare Directive
(2011/24/EU) was established in 2010. This 
is the framework for the development of 
the future paediatric oncology European 
Reference Network (via the ExPO-r-Net 
project).
g The Clinical Trials Regulation (536/2014/
EU) is expected to enter into force in 2016 
and to facilitate academic trials, and SIOPE 
will help European institutions and ECTGs 
to implement their trials within the new 
Regulation (through the CTF platform, 
see above) and ensure that experiences, 
issues and hurdles encountered in 
paediatric haematology-oncology are fed 
back to the relevant bodies.
g The Data Protection Regulation
(2012/0011(COD)) is under discussion at the 
time of the publication. In its current form, 
it would be detrimental to outcome 
 
research in paediatric oncology – a 
major objective of the SIOPE Strategic 
Plan – as well as to the interdisciplinary 
research collaborations involving different 
institutions, in order to ensure the best 
quality of care to the patient. SIOPE is 
joining oncology stakeholders to ensure 
that the needs of academic research and 
epidemiology are taken into account.
g The Paediatric Medicine Regulation
 (1901/2006/EC and 1902/2006/EC) 
entered into force in 2007. The European 
paediatric oncology community is engaged 
in pushing for immediate changes to 
its implementation, in order to better 
address the unmet needs of children 
and adolescents with cancer. Because 
cooperation between all stakeholders 
(patients, survivors, parents, academia, 
industry, regulators) is crucial, the CDDF-
SIOPE-ITCC multi-stakeholder paediatric 
platform (see above) was created to 
propose the immediate changes and to 
prepare for the revision of the Regulation, 
which could occur in 2017.
Cross-tumour programmes
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g In the 2015 Health programme, the
European Commission called for a Joint 
Action on Rare Cancers that will be 
implemented jointly with EU Member 
States. This will provide the framework 
for the implementation of part of the 
SIOPE Strategic Plan and for cooperation 
with adult oncology in the field of rare 
cancers.
In 2014, SIOPE effectively obtained the 
commitment of EU institutions and 
civil society representatives to support 
young people with cancer, through their 
endorsement of the SIOPE-ENCCA-ICCCPO 
Manifesto for Paediatric Oncology. This 
document was signed by 20 members of the 
European Parliament, setting up objectives 
to advance childhood cancer research, 
treatment and care. After the European 
elections, this document became an even 
stronger advocacy document for SIOPE on 
the long-term.
Additionally SIOPE and the European 
paediatric haematology-oncology 
community will contribute to the 
development of oncopolicy in Europe in the 
fields of multidisciplinary care, access to 
innovation and development of e-Health. 
SIOPE will join efforts with the European 
CanCer Organisation (ECCO) along with 
European Society for Medical Oncology 
(ESMO) and other European societies.
Training and education programme
The aim of this programme is to encourage 
high quality clinical and basic research as 
well as the delivery of high quality care in 
paediatric oncology throughout Europe. 
This is a remit of SIOPE and focuses on the 
organisation of educational courses and 
on the revision of the training syllabus in 
paediatric oncology.
SIOPE is involved in several training courses 
to develop the knowledge of health 
professionals on new and state-of-the-art 
therapies and allow them to gain more 
practical skills in the treatment of paediatric 
malignancies:
g The SIOPE-ESO Masterclass in paediatric
oncology: practice-oriented training 
with a focus on the application of the 
most recent research findings to clinical 
practice;
g The ECCO-AACR-ASCO workshop on
“Methods in clinical cancer research” in 
Flims, Switzerland: introduction of junior 
clinical oncologists to the principles of 
good and innovative clinical trial design 
and methods;
g The SIOPE-ENCCA-ENTYAC European
Course on the treatment of teenagers and 
young adults (TYA) with cancer: centred 
around multiple disciplines;
g The joint SIOPE-ESMO training
 programme on TYA.
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“The EU Data Protection Regulation is a debatable piece of legislation which 
could threaten childhood cancer clinical research” (Nikolaus Forgó, Institute 
for Legal Informatics, DE)
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Communication
The SIOPE Strategic Plan relies on timely, 
relevant and tailored communication to 
target stakeholders Based on its expertise 
of information-sharing with members 
and leading EU projects’ dissemination, 
SIOPE has set up a communication 
strategy, encompassing the pan-European 
haematology-oncology community, 
decision-makers and the general public. 
The communication objectives are: 
1. Uniting the community: further
increasing the profile of SIOPE as the 
main reference point for paediatric 
haematology-oncology in Europe, to 
stimulate cross-border exchange of 
best practices, to strengthen existing 
collaborations and to develop new ones;
2. Raising awareness: by fostering the 
well-informed involvement and 
commitment of target stakeholders and 
 by raising awareness of paediatric cancers 
across Europe in partnership with parents 
and survivors.
3. Generating action: translating the needs
 of the Strategic Plan as well as the SIOPE 
position and requests into legislative, 
funding, advocacy, partnership-building 
and further communication initiatives.
As part of the work of the European 
Academy of Paediatrics, SIOPE revised its 
previous syllabus with the aim of having a 
comprehensive document for the whole
of the EU that details the requirements 
expected from a trainee in paediatric 
haematology-oncology. The new version 
of the syllabus proposes a programme 
containing core knowledge and practical 
aspects related to approaches for diagnosis 
and treatment that are essential for all 
trainees in paediatric haematology-oncology 
(available on the SIOPE website: www.
siope.eu). 
From AIEOP. Credit Attilio Rossetti photographer, Italy
 “Europe should have a European Paediatric Cancer 
Plan addressing both care and research.” 
(Participants at the SIOPE-ENCCA Conference, 18-19 
September 2014)
Partnership with patients, survivors 
and parents
Building a partnership with patients, 
survivors, and parents’ organisations is 
essential to achieve the goals of SIOPE in 
terms of research, equal access to standard 
care and expertise, advocacy when new 
policies are developed and strategic 
decisions made at the national and European 
levels.
Childhood Cancer International (CCI) is a 
worldwide childhood cancer organisation 
that represents families of children with 
cancer and childhood cancer survivor groups. 
SIOPE has been working with the CCI Europe 
Regional Committee for several years, 
including partnerships in several European 
projects and initiatives.
In 2011 the Parent and Patient Advocacy 
Committee (PPAC) within ENCCA was 
created with CCI Europe Region Committee 
members, and consists of representatives 
from different national parents and survivors 
organisations. Since then, they have 
been building networks between parent 
and survivor groups and organisations, 
disseminating health policy-related issues 
within Europe and improving the training 
of representatives of patients survivors and 
parents in clinical research to make them 
powerful advocates and partners in this field. 
ENCCA, SIOPE and PPAC also worked
together in joint research and dissemination 
activities, as well as the development of a 
long-term sustainable strategy for paediatric 
oncology in Europe, the present SIOPE 
Strategic Plan and the seven medical and 
scientific objectives.
SIOPE and the CCI Europe Regional 
Committee entered into a co-operative 
relationship in order to implement the 
European long-term Strategic Plan and to 
raise awareness on cancer in children and 
adolescents. They signed a Memorandum 
of Understanding that sets out the 
specific areas of cooperation along with 
the principles by which both parties will 
run the partnership. The four areas are: i) 
ethics and social sciences and humanities, ii) 
access to standard of care and expertise, iii) 
improvements to the regulatory and political 
environment at the pan-European and 
national level, iv) research and development.
Partnerships
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Partnership with adult oncology
During the last 50 years, paediatric 
oncology has developed in relative isolation. 
Improving the cooperation of all paediatric 
haematologists and oncologists was 
the crucial objective so that an effective 
European clinical research programme could 
be set up and address the very specific 
needs of children with cancers without 
reference to adult cancer services.
It is now recognised that adult and 
paediatric oncology have a lot to share 
and learn from each other, and that 
collaboration is beneficial in order to 
address common goals and challenges:
g Care and research for rare cancers,
in terms of innovative methodology to 
evaluate new treatments and in terms 
of health care organisation models to 
provide access to expertise for patients 
suffering from rare and extremely rare 
cancers;
g Care and research for TYA (see above);
g Access to essential medicines, since most
anti-cancer drugs are used to treat 
both adult and paediatric cancers, even 
though there are differences in the 
tumours;
g European initiatives on care and research
oncopolicies.
SIOPE and ESMO (the European Society 
of Medical Oncology) have decided to 
develop a joint initiative to address those 
topics, and established a Memorandum of 
Understanding to help this collaboration.
Partnership with paediatric 
haematology-oncology in other 
continents
SIOPE is part of the global paediatric 
oncology agenda run by the International 
Society of Paediatric Oncology (SIOP). 
Several European-centred study groups 
have an international scope, and bring 
together global investigators to participate 
in a common clinical trials portfolio. 
The IBFM-study group is international, and 
patients from countries outside Europe 
participate to its leukaemia trials and 
translational research projects. 
More than a hundred institutions from 
Europe, Asia, Central and South America, 
Australia and New Zealand collaborate in 
SIOPEL, the SIOPE-liver study group. Early 
drug trial groups such as ITCC in Europe, 
the Pediatric Oncology Experimental 
Therapeutics Investigator’s Consortium 
(POETIC) and Therapeutic Advances in 
Childhood Leukemia and Lymphoma (TACL) 
in North America, the Canadian C17 network, 
the Australia Children’s Cancer Trials group 
and the Children Oncology Group (COG) 
phase I consortium are working together 
to speed up the development of new 
anticancer agents.
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SIOPEN has built with COG and neuro-
blastoma groups from Japan, China and 
Australia a large clinical and biological 
database of more than 9,000 neuro-
blastoma patients in order to define and 
validate new staging system and new 
biological prognostic biomarkers through 
the International Neuroblastoma Research 
Group [9] [22]. 
Groups such as the SIOP-Renal Tumours 
Study Group support clinical trials groups 
in other continents that run studies using 
the same standard treatment backbones, 
adapted to local circumstances.
The COG and the European Inter-group 
for Childhood non Hodgkin lymphoma 
(EICNHL) are currently running a 
randomised phase III clinical trial to evaluate 
the addition of rituximab, an anti CD20 
monoclonal antibody, on standard intensive 
chemotherapy treatment in high-risk 
Burkitt’s lymphoma.
The European and American Osteosarcoma 
Study Group (EURAMOS) has successfully 
completed a large phase III study with 
partners, which included the COG, the 
European Osteosarcoma Intergroup, the 
Cooperative Osteosarcoma Study Group, 
and the Scandinavian Sarcoma Group. 
The EURAMOS Strategy Group, made 
up of these four multi-national groups, 
as well as the relevant Australasian, 
French, Italian, Japanese, and Spanish 
osteosarcoma groups, is exploring options 
for collaboration on an even larger platform.
In the next 10 years, international coope-
ration will be reinforced to evaluate 
innovative targeted drugs within
extremely small and rare groups (defined 
by biomarkers), such as children with 
B-RAF mutated malignancies. Even in 
less rare clinical situations, international 
randomised clinical trials will be considered 
more regularly to speed up evaluation of 
innovative therapies. 
Partnership with industry
For the last 50 years, progress has been 
made in curing paediatric cancers by running 
academic trials using anti-cancer drugs 
that are available in hospital pharmacy 
departments. Pharmaceutical companies 
have not developed their anti-cancer agents 
in the paediatric population, and nearly 
half of drugs used daily to cure cancer in 
children and adolescents do not have the 
regulatory official authorisation, stated in 
the ‘Summary of Product Characteristics’.
In Europe this situation has significantly 
changed over the last five years because 
regulatory initiatives, first in the U.S. and 
then in Europe, obliged pharmaceutical 
companies to test their drugs in the 
paediatric population when relevant. 
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There was indeed an urgent need to access 
new drugs developed by pharmaceutical 
companies as early as possible during their 
development in adults, and to avoid families 
moving to the US to get access to innovative 
therapies in development.
Thanks to the EU Paediatric Medicine 
Regulation, pharmaceutical companies and 
academia have started to work together, to 
evaluate oncology drugs within paediatric 
investigation plans. This is a learning 
curve for everyone since pharmaceutical 
companies are not accustomed to working 
with paediatric oncologists and vice versa.
The goal is to develop ‘intelligent and 
transparent’ partnerships that recognise 
the specificities of paediatric haematology-
oncology, i.e. a well-structured arena for 
clinical research, dealing with rare and 
complex situations, while the paediatric 
development of oncology drugs is, by 
definition, a pre-competitive research 
activity for pharmaceutical companies and 
competition to access rare patients makes 
no sense.
A new model of cooperation between 
pharmaceutical companies, academia and 
public-private partnership needs to be 
developed in order to adequately address 
the needs of children and adolescents with 
cancer and regulatory requirements. This 
is being addressed in the CDDF-SIOPE-ITCC 
paediatric oncology platform. In addition, a 
strategy will be implemented to encourage 
investment and partnership with small 
pharmaceutical companies to develop drugs 
against specific paediatric targets.
Partnership with charities
In several EU Member States, charities 
are extremely efficient at fundraising to 
support research and care for children and 
adolescents with cancer. These efforts are 
developed at the national level and can be 
fragmented, with significant differences 
between countries.
Most research programmes are run at the 
European level, and there is a need to figure 
out how charities from different countries 
can be more efficient at jointly funding large 
and ambitious European programmes.
SIOPE will propose to charities to fund 
and co-fund European projects and 
programmes. By defining, implementing 
and coordinating a long term sustainable 
Strategic Plan, SIOPE and the European 
paediatric haematology-oncology are willing 
to provide a transparent and clear visibility 
to the projects that will be run within a well-
defined and integrated framework. 
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By definition, funding of the now established European strategy in paediatric haematology-
oncology will come necessarily from several sources: the European Commission, national 
funding bodies, charities and foundations, industry as well as  anyone willing to invest in 
paediatric oncology research and development.
European funding is available for research projects through Horizon 2020 calls.  Projects in 
paediatric haematology oncology will be submitted to relevant European calls by SIOPE, 
groups and institutions as part of the implementation of the SIOPE Strategic Plan and referred 
as such in their application.  
The critical hurdle encountered in paediatric haematology-oncology, as well as in other 
research areas, is the lack of funding for structures that are needed to run a coordinated and 
integrated research agenda. To this extent, in 2011 the European Commission provided €12m 
to structure oncology research into children and adolescents. One of the best examples of the 
goals achieved is the long-term sustainable Strategic Plan described in this document. ENCCA 
illustrates how funding for a permanent structure is essential to achieve progress and deliver 
success.
ENCCA will finish on December 2015 and the decision was taken that SIOPE will run the on-going 
agenda. The key question is how to fund the projects, the programmes and the structures that 
are needed to implement the long-term sustainable strategy.
At the end of the SIOPE-ENCCA event, which shared the European Strategic Plan with 
all stakeholders in Brussels in September 2014, the participants proposed to develop a 
European Cancer Plan for Children and Adolescents. This plan would show the commitment 
of the EU and its Member States to address childhood and adolescent cancers as a priority and 
a strategic objective for the European Union. Specific European initiatives would be set up to 
join efforts from the EU and its Member States for funding. In addition, it would allow other 
co-funding bodies to contribute to a pan-European initiative.
Funding strategy
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List of acronyms/glossary
• Biobank: A type of biorepository that stores biological samples (usually human) for use in research
• Biomarker: Generally refers to a measurable indicator of some biological state or condition
• CCI: Childhood Cancer International
• CDDF: Cancer Drug Development Forum
• CNS: Central Nervous System
• COG: Children Oncology Group
• CRC/ECRC: European Clinical Research Council for paediatric and adolescent oncology
• CTF: Clinical Trial Facilitating platform
• DG SANTE: Directorate General for Health and Food Safety, European Commission 
• EAC: (ENCCA) Ethics Advisory Committee 
• EAC: (ENCCA) Ethics Advisory Committee
• ECCO: European CanCer Organisation
• ECTGs: European Clinical Trial group(s) in paediatric oncology
• EICNHL: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
• ENCCA: European Network for Cancer research in Children and Adolescents
• EORTC: European Organisation for Research and Treatment of Cancer
• EPAAC: European Partnership for Action Against Cancer
• ERN: European Reference Network(s)
• ESMO: European Society for Medical Oncology 
• EU: European Union
• EURAMOS: European and American Osteosarcoma Study Group
• FP5, FP6, FP7: EU 5th/ 6th/ 7th Framework Programmes for research and innovation
• Horizon 2020: EU Programme for research and innovation (2014-2020)
• I-BFM: International BFM Study Group
• ITCC: Innovative Therapies for Children with Cancer
• LTS: (ENCCA) Long-Term Sustainability (working group)
• MAC: Members of the Parliament (MEPs) Against Cancer group
• MOA: Mechanism(s) Of Action
• NaPHOS: National Paediatric Haematology-Oncology Society-ies
• PanCare: Pan-European network for Care of survivors after childhood and adolescent cancer
• PanCareSurFup: PanCare childhood and adolescent cancer SURvivor care and Follow-UP studies
• PICORET: Population Improvement in Childhood cancer Outcomes through Research, Evaluation and Training
• PIP: Paediatric Investigation Plan(s)
• POETIC:  Pediatric Oncology Experimental Therapeutics Investigators’ Consortium
• PPAC: (ENCCA) Parent and Patient Advocacy Committee 
• QUARTET:  QUAlity and excellence in RadioTherapy and imaging for children and adolescents with cancer across  
 Europe in clinical Trials
• SAB: (ENCCA) Scientific Advisory Board
• SIOPE:  SIOP Europe, the European Society for Paediatric Oncology
• SIOPEL:  SIOPE-Epithelial Liver Tumour Study Group
• SIOPEN:  SIOP Europe Neuroblastoma Group
• SSH:  Social Sciences and Humanities project
• TACL: Therapeutic Advances in Childhood Leukemia and Lymphoma
• TYA: Teenagers and Young Adults
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